Saturday 17 October 2026
Export VRPX’s income statement to Excel — free account
Virpax Pharmaceuticals, Inc.
VRPX Healthcare Biotechnology
In the quarter to December 2024, EPS grew 153.6% and free cash flow grew 4.68%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow VRPX
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
| (2,364.98%) | (594.46%) | (362.29%) | (241.52%) |
+8 more TTM periods Free account |
|
| (215.80%) | (198.45%) | (185.81%) | (156.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,320.56% | 645.30% | 616.46% | 1,391.91% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(98.20) | (90.47) | (190.08) | (332.79) | |
Free Cash Flow |
(16.71) | (16.85) | (15.04) | (15.57) | |
| Other line items | |||||
Cash ROIC |
(2,788.74%) | 828.44% | 1,627.56% | (2,386.20%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(117.40) | (101.44) | (240.22) | — | |
Operating CF/Net income |
1.39 | 1.27 | 0.87 | 0.92 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(98.20) | (90.47) | (190.08) | (332.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates